Introduction and hypothesis Intravesical botulinum toxin A (BTX-A) is emerging as a potential new treatment for refractory interstitial cystitis (IC). However, there has been conflicting evidence on this treatment's effectiveness. The aim of our systematic review was to assess the effectiveness and adverse effects of intravesical BTX-A in IC. Methods Randomised controlled trials (RCTs) and prospective studies of relevance were identified, assessed for inclusion and then analysed by two independent reviewers. Results Ten (three RCTs and seven prospective cohort) studies with a total of 260 participants were included. Eight studies reported improvement in symptoms. Urodynamic parameters were variable. Meta-analysis was not performed due to heterogeneity in reporting of outcomes. Some adverse events, e.g. dysuria and voiding difficulty, were noted (19 out of 260 were required to self-catheterise at anytime postoperatively). Conclusions The evidence from the studies thus far suggests a trend towards short-term benefit with intravesical BTX-A injections in refractory IC, but further robust evidence should be awaited.
Introduction
The European Society for the Study of Interstitial Cystitis/ Painful Bladder Syndrome (ESSIC) uses the term bladder pain syndrome (BPS) instead of interstitial cystitis (IC) and/ or painful bladder syndrome (PBS). ESSIC proposes that BPS would be diagnosed on the basis of chronic (>6 months) pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency. Confusable diseases as the cause of the symptoms must be excluded. Further documentation and classification of BPS might be performed according to findings at cystoscopy with hydrodistension (HD) and morphological findings in bladder biopsies [1] . This is also supported by the Bladder Pain Committee of the International Consultation on Incontinence [2] . Formerly, the term IC was used for patients with 'typical cystoscopic and histological features'. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) definition of IC requires objective findings of glomerulations or Hunner's ulcer at cystoscopy and subjective symptoms of bladder pain or urinary urgency and also includes multiple exclusion criteria such as age<18 years, duration of symptoms <9 months and absence of nocturia [3] . IC/BPS is far more common in women than in men. Of the estimated 1.3 million Americans with this syndrome, more than 1.2 million are women [4] . Median age of onset is 40 years and up to 50% of women experience spontaneous remissions unrelated to treatment, with a duration ranging from 1 to 80 months [5] . IC is a difficult condition to treat and, according to one study, 183 different therapies had been used [6] . The treatments include nonpharmacological measures such as dietary modification, lifestyle interventions/behavioural therapies, bladder training, peripheral transcutaneous nerve stimulation, pharmacological treatments such as oral medication, intravesical or bladder instillation therapy and surgical interventions like sacral neuromodulation and diversion. In recent years, intravesical injection of botulinum toxin A (BTX-A) has been explored as a new therapeutic option for BPS/IC. BTX-A is an extremely potent neurotoxin derived from the anaerobic bacterium Clostridium botulinum and acts by inhibiting the release of the neurotransmitter acetylcholine at the neuromuscular junction thereby decreasing muscle contractility at the injection site. The rationale for using BTX-A in BPS/IC is that it might have an antinociceptive effect on bladder afferent pathways [7] . We aimed to assess the effectiveness and safety of BTX-A in the treatment of IC/BPS by means of a systematic review.
Material and methods

Literature search
Studies for inclusion in the review were identified by searching the MEDLINE, EMBASE, CINAHL, CENTRAL (The Cochrane Library, Issue 2, 2009), MetaRegister of Controlled Trials and The National Library for Health from inception to June 2009 for relevant publications using relevant subject headings from each database. The following keywords were used for the search as text words without language restriction using The National Library for Health search 2.0 Healthcare Databases Advanced Search interface: 'botulinum toxin', 'botox', 'interstitial cystitis', 'dysport', 'pelvic pain' and 'painful bladder'. Two reviewers (ST and DA) independently assessed the titles and abstracts. The full paper was obtained if either reviewer considered the reference potentially relevant. Hand searches of the bibliographies and citation lists of all relevant reviews were also carried out to identify any missing studies not captured by electronic searches and potentially eligible studies were obtained as full reports. In addition, proceedings of the International Urogynecological Association and International Continence Society of the last 2 years were searched for abstracts as were the documents available on the website of the International Painful Bladder Foundation (June 2009).
Study selection
Randomised controlled trials (RCTs) or quasi-RCTs and prospective studies of participants who had intravesical BTX-A injections for BPS/IC with or without meeting the NIDDK criteria were included. Studies assessing the effect of BTX-A along with other interventions and/or studies assessing the effect of intravesical instillation with BTX-A in patients with BPS/IC were excluded. Two reviewers (ST and DA) assessed the eligibility of full papers against the review inclusion criteria, with disagreements resolved by discussion, if necessary, with a third reviewer (PL). In cases of duplication, the study which reported the most recent data results was included.
Data extraction
Two reviewers independently assessed methodological quality and extracted data on participants' characteristics, intervention, outcomes and adverse effects from the included studies using a purpose-designed proforma. All manuscripts meeting the selection criteria were assessed for their methodological quality. Quality was defined as the confidence that the study design, conduct and analysis minimised bias in the estimation of test accuracy. The NewcastleOttawa scale [8] was used to assess the quality of included nonrandomised studies and Jadad score for RCTs [9] .
Types of participants
Participants in included studies were adult male and female patients with a clinical diagnosis of BPS/IC, with or without meeting the NIDDK criteria. Patients who had chemical or radiation cystitis were excluded. Intervention BTX-A injections injected submucosally into the bladder wall via cystoscope (rigid or flexible) under local anaesthesia (LA)/general anaesthesia (GA) with or without involving trigone.
Outcome measures
Most studies used clinical parameters such as frequency, nocturia and pain and different instruments such as the Bristol Female Lower Urinary Tract Symptoms Questionnaire (BFLUTS), Global Response Assessment (GRA), Incontinence Impact Questionnaire (IIQ), Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), King's Health Questionnaire (KHQ), O'Leary-Sant Questionnaire, quality of life (QoL) from International Prostate Symptom Score (IPPS), Urogenital Distress Inventory (UDI) and Visual Analogue Score (VAS) to assess outcomes. Various urodynamic parameters such as maximum cystometric capacity (MCC), first desire to void (FDV), bladder compliance, first sensation of filling and detrusor pressure were assessed in most studies. Figure 1 summarises the flow for study selection in the systematic review. Initially, we identified 14 potential studies of which 10 were eligible for analysis [7, [10] [11] [12] [13] [14] [15] [16] [17] [18] and four out of these were published as abstracts [12] [13] [14] 16] . Four studies were excluded from the review as they did not meet the inclusion criteria [19] [20] [21] [22] and one trial has just completed recruitment and the estimated study completion date is December 2010 [23] . The 10 studies that we analysed included three RCTs [11, 15, 16] and seven prospective nonrandomised studies [7, 10, 12-14, 17, 18] . Table 1 gives the details of patient characteristics, inclusion and exclusion criteria, intervention details and various outcomes including complications for nonrandomised prospective studies. Details of the patients, interventions, comparison and outcomes of RCTs are given in Table 2 . There were a total of 260 participants (213 women and 18 men); one study with 29 patients did not report the sex of the participants [12] . The studies included patients between the ages of 18 and 83 years (mean age, 49.9 years). The included studies were uniformly small with sample sizes ranging from 10 to 67. Five studies used the NIDDK criteria for diagnosing IC [7, 11, 12, 15, 17] , one study used clinical symptoms and presence of sterile urine to diagnose IC [18] , whereas another study used clinical symptoms and cystoscopy to diagnose IC [10] . The criteria for diagnosing IC/BPS were not mentioned in three studies [13, 14, 16] . Preparation of BTX-A used was Botox (Allergan, Inc., Irvine, CA, USA) in five studies, Dysport (Ipsen Ltd., Slough, Berkshire, UK) in two studies [12, 16] and was not mentioned in two studies [15, 17] . In the two-centre case series [7] , Dysport was used to treat Polish patients and Botox was used for US patients. The dose of BTX-A used varied between the studies, sometimes changing within the study [17] . The amount of BTX-A injected was mostly 100-300 U (mostly at a concentration of 10 U/1 ml normal saline), except for two studies which used 500 U Dysport [12, 16] . In most studies, the number of injection sites in the bladder was between 20 and 30, except in two studies; in one, 10 injections were performed in the bladder trigone only [13] and, in the other study, injections in 40 sites in the posterior and lateral walls of the bladder were given [11] . Injection sites included trigone in four studies [10, 12, 15, 18] and trigone was spared in two studies [14, 16] and, in the remaining studies, it was not clearly mentioned whether trigone was injected or not. In most of the studies, BTX-A injections were done under general anaesthesia although some were done under sedation [7] or under local anaesthetic [14, 15] . Duration of follow-up varied between 3 and 24 months across studies. Only one study reported that seven out of 29 patients needed repeat injections because of recurrence of pain at 6 months [12] .
Results
Methodological quality of included studies
All except one study [14] had patients who were representative of this condition in the population (details in Table 1 ). The ascertainment of diagnosis, assessment of outcome and the instruments used to assess outcomes were satisfactorily described in all studies. The length of follow-up was described in six out of seven studies and, in four out of seven studies, <20% of patients were lost to follow-up (Table 3 ). All RCTs were scored using a scale of 1 to 5 on the Jadad scale. One RCT [16] was of high quality (Jadad score of 5), the second one scored 3 on the Jadad scale [11] and the third one was of low methodological quality (Jadad score of 1) [15] .
Effectiveness
Out of 10 studies, eight (including two RCTs) reported improvement in some or all of the following: frequency, pain, voided volume and QoL. The urodynamic parameters were variable. It is noteworthy that the two studies that reported no improvement with BTX-A used trigone-sparing technique [14, 16] . It was not feasible to perform metaanalysis as there was heterogeneity among the studies in definition of condition, design of the study, dose, method of intervention, outcome measures/assessment tools, length of follow-up, etc.
Adverse effects
The use of the regimen was generally well tolerated although mild adverse events such as dysuria, temporary >100 ml and two patients had PVR >200 ml) at any time postoperatively. Thirty-five patients complained of dysuria or pain exacerbation after treatment and 18 out of 260 had impaired detrusor contractility or mild difficulty in urination but were able to empty bladder completely with straining. Four patients developed temporary haematuria and four patients had UTI following the procedure.
Discussion
The limited evidence from the included studies suggests that intravesical BTX-A injections may be the appropriate therapy for patients with refractory IC and there is a trend towards benefit. To the best of our knowledge, this systematic review, with the data that was utilised, summarises all the prospective nonrandomised studies and RCTs that exist on this topic. There are several strengths of this review. The review addressed a clear question. The search was thorough and systematic without language restrictions. Two reviewers independently did the study selection and data extraction to minimise errors. We attempted to contact authors of published and unpublished studies to obtain further details.
The trials were of small sizes with short-term follow-up. We could not get more details on some of the abstracts in spite of attempting to contact the authors. Analysing the efficacy of BTX-A injections in the treatment of IC/BPS is challenging because of the heterogeneity of the definition of BPS, different methods and doses of injection of Botox, varied number of outcome measures employed and small number of participants. Hence, firm conclusions cannot be drawn about the effectiveness of intravesical BTX-A injection in the treatment of BPS.
Intravesical BTX-A may be advantageous in selected patients with refractory BPS who have failed to respond to conventional treatments. However, we agree that it should be ideally used in clinical trial setting [24] pending further evidence. The review has shown the clear need for further randomised trials that are methodologically sound and sufficiently powered with adequate follow-up. Furthermore, study design should include assessing the optimum dose and sites of BTX-A injection and duration of efficacy. Better concordance or uniformity between studies in terms of defining the condition and use of instruments measuring quality of life will aid in future interpretation of data and clinical application. 
